Why Immutep's Stock Is Trading Higher Today

Immutep IMMP shares are trading higher on Wednesday after the company was granted a European patent for its IMP761.

Immutep is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its lead product is IMP321, which involves in clinical development for the treatment of cancer indications.

Immutep shares traded up 9.15% to $1.79 on Wednesday at the time of publication. The stock has a 52-week high of $3.10 and a 52-week low of 53 cents.